Brilaroxazine
Small moleculeexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Dec 1, 2011 (NCT01490086)
Timeline
Indications
Mechanism of action
- Dopamine D2 receptorPARTIAL AGONIST
DRD2 partial agonist
- Serotonin 1a (5-HT1a) receptorPARTIAL AGONIST
HTR1A partial agonist
- Serotonin 2a (5-HT2a) receptorPARTIAL AGONIST
HTR2A partial agonist
- Serotonin 2b (5-HT2b) receptorANTAGONIST
HTR2B antagonist
- Dopamine D3 receptorPARTIAL AGONIST
DRD3 partial agonist
- Dopamine D4 receptorPARTIAL AGONIST
DRD4 partial agonist
Chemistry & pharmacology
Loading structure…
SMILES
O=C1COc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1- Mol. weight
- 450.37 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095172 ↗
Also known as
- rp5000
- rp5063
- rp5063
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05192304 | Phase 1 | Feb 1, 2022 | Jiangsu Kanion Pharmaceutical Co., Ltd, Jiao Tong University |
| NCT05184335 | Phase 3 | Jan 24, 2022 | Reviva Pharmaceuticals |
| NCT03931668 | Early Phase 1 (Phase 1) | Apr 17, 2019 | Jiangsu Kanion Pharmaceutical Co., Ltd, Jiao Tong University |
| NCT01490086 | Phase 2 | Dec 1, 2011 | LabCorp, Reviva Pharmaceuticals |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiangsu Kanion Pharmaceutical Co., Ltd | For profit | 2 | 1 | 1 | 2019 |
| Jiao Tong University | Academic/Hospital | 2 | 1 | 1 | 2019 |
| Reviva Pharmaceuticals | For profit | 2 | 2 | 2 | 2011 |
| LabCorp | For profit | 1 | 0 | 1 | 2011 |
4 organizations
Page 1 / 1